Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.

Liliana Antunes Clara Mazagatos Iván Martínez-Baz Reinout NaesensMaria-Louise BorgGoranka Petrović Terra V Fatukasi Ligita Jancoriene Ausenda Machado Beatrix Oroszi Petr Husa Mihaela Lazar Ralf Dürrwald Jennifer Howard Aryse Martins Melo Gloria Pérez-Gimeno Jesús CastillaEva BernaertAušra Džiugytė Zvjezdana Lovrić Makarić Margaret FitzgeraldAuksė MickienėVerónica Gómez Gergő Túri Lenka Součková Alexandru Marin Kristin Tolksdorf Nathalie Nicolay Angela M C Rosenull null

Published in: Influenza and other respiratory viruses (2024)

We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Keyphrases